key: cord-0779593-c010xjsv
authors: Kamarullah, William; Sabrina, Adelia Putri; Rocky, Marthin Alexander; Gozali, Darius Revin
title: Investigating the implications of COVID-19 outbreak on systems of care and outcomes of STEMI patients: A systematic review and meta-analysis
date: 2021-06-25
journal: Indian Heart J
DOI: 10.1016/j.ihj.2021.06.009
sha: 673df2a054129b9b6405106b5225fde41bed80b0
doc_id: 779593
cord_uid: c010xjsv

INTRODUCTION: There has been a concern whether the decrease in ST-segment elevation myocardial infarction (STEMI) cases during the COVID-19 pandemic era is related to unsatisfactory performance of STEMI systems of care as well as worsening of the clinical outcomes in STEMI patients. Thus, our meta-analysis was conducted to evaluate this matter. METHODS: We compared the predetermined variables in this meta-analysis during the early and late pandemic. Using a combination of adapted search terms to fit the requirements of several search engines (PubMed, EuropePMC, SCOPUS, ProQuest, and EBSCOhost), we reviewed all observational studies citing our outcomes of interest before and during the outbreak. RESULTS: Thirty-five records comprising a total of 62,247 participants were identified. Overall, our meta-analysis showed that there was a huge reduction of nearly 80% for STEMI admission during the outbreak (n = 10,263) in contrast to before the outbreak period (n = 51,984). STEMI patients who were admitted during the outbreak received less primary PCI and had longer symptom-to-FMC (first medical contact) time along with prolonged door-to-balloon (DTB) time. A decrease in the achievement of final TIMI (thrombolysis in myocardial infarction) 3 flow after primary PCI was also observed in this study. However, the number of in-hospital mortality was similar between two groups. CONCLUSION: There was a decrease in the STEMI care performance and worsening of clinical outcomes in STEMI patients, especially in the early pandemic period. Overall, concise health services must be implemented following a responsibility to obey health protocols to deliver high-quality services related to STEMI systems of care amidst the global pandemic.

The year 2021 marks the anniversary of the World Health Organization (WHO) official announcement of novel coronavirus disease 2019 (COVID- 19) pandemic. The outbreak has caused a massive global burden, leading to a major interference in medical services and a death toll up to 3.22 million people worldwide. 1 The impact given, especially on time-sensitive health services such as primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) setup, appears to be greater. Several studies reported that hospital admissions related to coronary heart disease, especially in STEMI cases, tend to decrease dramatically contrasted to the period before the pandemic. 2e4 The shift in management that originally recommended the use of fibrinolytic therapy in STEMI cases during early pandemic, has changed into reperfusion therapy in the form of primary PCI considering a more superior end result. 5 However, the decline in STEMI cases and its relationship to the performance of STEMI systems of care remains questionable. Inconsistent results across the studies make it impossible to determine the effect of the COVID-19 pandemic on mentioned issues, especially the aftermath given to several clinical outcomes. For instance, mortality and predictors of satisfactory prognosis which of course affect STEMI patients' quality of life. 6, 7 Hence, this meta-analysis was designed to evaluate the effect of the COVID-19 pandemic on the delivery of care systems and clinical outcomes in STEMI patients.

This systematic review and meta-analysis was written based upon the Cochrane handbook for systematic reviews of interventions and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). 8 The research protocol has been registered at the International Prospective Register of Systematic Reviews (PROSPERO) under registration number CRD42021250716.

Since we performed systematic review and meta-analysis of observational studies, we systematically search relevant articles through several search engines including PubMed, EuropePMC, SCOPUS, ProQuest, and EBSCOhost investigating comparisons between systems of care and clinical outcomes in STEMI patients before and during the COVID-19 pandemic from the time in which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified (January 2020) up until April 2021. We utilize minimum keywords (STEMI AND COVID-19) to maximize the initial scope of research in order to ensure the largest amount of articles recorded. Moreover, hand search from the references of included studies were screened to broaden our search results. The complete search and screening processes were contained in PRISMA flow chart presented in Fig. 1. 

In the present study, we included either prospective or retrospective observational studies containing our data of interest. Our study population was STEMI patients described as the presence of ischemic heart symptoms for more than 20 minutes accompanied by elevation of the ST-segment at least two contiguous electrocardiogram (ECG) leads or characterized by a new onset left bundle branch block. 9 The studies should report specifically on the primary outcomes of the STEMI systems of care performance consisting number of primary PCI performed, door-to-balloon (DTB) time, and final TIMI (thrombolysis in myocardial infarction) 3 flow accomplishment after PCI. Secondary outcomes included symptom-to-FMC (first medical contact) time and in-hospital mortality. Supplied data must be described in a comparative manner amid the COVID-19 pandemic period with pre-pandemic group. The comparator group was a group that existed prior to the pandemic for a same given period of time. Animal studies, expert opinions, literature review studies, news articles, letters, editorials, guidelines, and any studies that did not mention the outcomes of interest were excluded from this study.

Extraction of relevant data and risk of bias assessment were carried out by two independent authors. We extracted several pertinent variables from the selected studies using predesigned table that comprised of name of the first author, year of publication, country from which the study was conducted, pre-pandemic and pandemic period, outcomes of interest (symptom-to-FMC time, door-to-balloon time, the amount of primary PCI carried out, final TIMI 3 flow after PCI, and in-hospital mortality). DTB time was calculated as the period of time between patient's admission at PCI center and first device introduction in order to reopen the occluded coronary vessel(s). 9 Symptom-to-FMC time was defined from in which the first symptom onset to emergency department admission at PCI center. 9 Several confounding factors that could potentially affect the effect size of study outcomes e.g. age, sex, hypertension, diabetes mellitus, dyslipidemia, family history of coronary artery disease (CAD), smoking status, Killip class >1, anterior myocardial infarction (MI), and multiple coronary artery involvement were also involved in the data extraction process for regression purpose. Dichotomous data were reported in terms of frequencies and/or percentages, while mean and standard deviation were used assuming the data were continuous. If the study did not report mean and standard deviation, estimation was utilized using a method proposed by Wan et al 10 . Disagreements regarding study selection and data extraction were resolved through consensus or by a third reviewer.

Quality assessment was performed using the NewcastleeOttawa Scale (NOS). 11 Each article received a score to indicate their degree of bias (low [included] and high [excluded] ). If studies receive a total score of seven or above, the study was considered having a low risk for bias. Otherwise, if studies receive a total score of six or below, that means the study was ascertained to have a high risk of bias and excluded from this meta-analysis. Discrepancies in quality ratings were resolved by discussion with a third reviewer.

We used STATA: Software for Statistics and Data Science 16.0 version to measure the overall effect size in this meta-analysis. Acquired data for each study's endpoint which was converted into dichotomous data were analyzed using the Mantel-Haenzel method and pooled as risk ratio (RR) to measure the effect size. For continuous data, the generic inverse variance method was used and standardized mean difference was employed as an effect measure. The pooled outcomes were calculated through computative random-effects model regardless of their heterogeneity. To make an optimized, more robust summary across the included articles, we performed subgroup meta-analysis and divided it based on COVID-19 pandemic period into early and late pandemic stage. As the World Health Organization (WHO) declared COVID-19 as a pandemic in March 2020, 12 mid April 2020 was chosen as the cutoff point for the mentioned subset evaluation. To investigate potential sources of heterogeneity among included studies, we performed restricted-maximum likelihood meta-regression using potential covariates mentioned in previous sub-heading. Additionally, any statistically significant confounding variables will be added into subgroup analysis using median-split method. Finally, Begg's funnel plot was used to detect any publication bias. All statistical tests were two-sided, and P < 0.05 indicated statistical significance.

According to the predetermined search strategy, there were a total of 1258 studies obtained from five different search databases of which two of them were obtained throughout hand searching process. After excluding 25 duplicate records, a screening process for titles and abstracts was carried out and a total of 91 eligible studies were remained. Additionally, 56 records were excluded based on several reasons: 1) outcomes of interest were not relevant (n ¼ 31); 2) a comparison between two period was not reported (n ¼ 16); 3) articles were case report/series (n ¼ 9). Eventually, a total of 35 studies with 62,247 participants 13e47 were evaluated in our meta-analysis. STEMI patients who presented in the pandemic period were older, predominately from male population, had a higher prevalence of comorbid conditions, and had worse cardiac function during hospital admission. The mean NOS of the included studies was 8.23 ± 0.69, indicating a low risk of bias. Complete data on baseline characteristics between three pandemic stages were provided in Table 1 .

The outline characteristics of STEMI care performance and clinical outcomes regarding STEMI patients were reported in Table 2 . Our meta-analysis showed that fewer people were visiting the emergency department for angina symptoms and the number of hospital admission regarding STEMI was dropped by almost 80 percent during COVID-19 pandemic in compare with pre-pandemic period (10,263 versus 51,984 patients respectively). In addition, our analysis revealed a statistically significant longer symptom-to-FMC time during pandemic as opposed to pre-pandemic time, especially in early pandemic subgroup (SMD ¼ 1.18, 95% CI ¼ 0.94e1.43, I 2 ¼ 98.1%, P < 0.001) (Fig. 2a) . Meanwhile, lesser rate of performed primary PCI was affirmed in the time of pandemic period and was 72% (53%e97%) of that during the overall pre-pandemic period but not in the late pandemic (Fig. 3a) . We also observed significant longer door-to-balloon time as the key of excellency in implementing STEMI care during the whole COVID-19 catastrophe (SMD ¼ 1.02, 95% CI ¼ 0.67e1.38, I 2 ¼ 99.1%, P < 0.001) (Fig. 4a) along with a 40% (12%e59%) decrease in the achievement of final TIMI 3 flow after primary PCI (Fig. 5a) . On the contrary, our pooled analysis showed no notable difference in mortality between two groups (RR ¼ 1.34, 95% CI ¼ 0.96e1.86, I 2 ¼ 83.5%, P ¼ 0.086) although significant distinction was noted during early pandemic time (RR ¼ 1.90, 95% CI ¼ 1.10e3.27, I 2 ¼ 33.2%, P ¼ 0.021) (Fig. 6a) . 

A further meta-regression analysis was performed to discover whether there was a correlation between potential covariates and outcomes of interest in this study. The results showed that the number of performed primary PCI, symptom-to-FMC time, and door-to-balloon time differences between two periods were not affected by the country developmental status. Apart from that, the variance in clinical outcomes observed in this meta-analysis (final TIMI 3 flow and in-hospital mortality) were also not influenced by age, gender, hypertension, diabetes mellitus, dyslipidemia, family history of CAD, smoking, Killip class >1, anterior MI, and multiple coronary artery involvement (P > 0.05).

Begg's funnel plot analysis showed qualitatively symmetrical funnel plots over all of the corresponding outcomes (Figs. 2be6b) and showed no indication of publication bias.

In our meta-analysis, we found that hospital admission for STEMI patients has significantly decreased during the COVID-19 outbreak. More importantly, the symptom-to-FMC and DTB time were longer along with a decline in the number of final TIMI 3 flow achievement during pandemic. However, the in-hospital mortality did not vary between two groups which deserve further discussion.

Avoiding hospital visits and the fear of SARS-CoV-2 exposure are alleged to be the main causes of the decline in STEMI cases during pandemic. Stay at home regulation and prohibition to visit public places, that occurred mostly during the early days of pandemic, are also thought to be the major factors in terms of longer symptom-to-FMC time as it was shown consistently across all studies within the early pandemic subgroup. 48, 49 Soon after the implementation of health campaign to keep seeking medical attention when experiencing symptoms of a heart attack, 50 there has been an improvement in the symptom-to-FMC time trend which was later confirmed through the late pandemic subgroup analysis throughout our study. Although tendency of improvement was observed, this emphasizes again the importance of not underestimating coronary heart disease and pursuing health care in conjunction with STEMI cases is an absolute necessity.

Conferring about the STEMI chain of survival could not be separated from the topic of primary PCI utilization. An interim guideline issued in China recently recommended the use of fibrinolytic therapy for STEMI patients attending healthcare facilities within 12 hours of symptom onset during this outbreak. 51 However, it should be noted that the success rate of fibrinolytic therapy in restoring occluded blood vessel flow has a much lower success rate when compared to PCI. 52 A quotation goes "time is muscle", which means that handling cases of myocardial infarction in the minimum possible time can save viable myocytes as maximum as possible. Nevertheless, prolonged door-to-balloon time was observed during the outbreak, particularly in the early pandemic subgroup. 9 This may have been caused by time-wasting COVID-19 screening which consists of epidemiological screening, swab specimen collection for polymerase chain reaction (PCR) testing, chest X-rays, and several other laboratory tests to prevent intrahospital transmission of COVID-19. Besides, the term "myocarditis associated with COVID-19", acknowledged as the most preeminent cause of myocardial infarction with non-obstructive coronary arteries (MINOCA) during this pandemic era could be one of the foremost differential diagnosis that should be considered by healthcare personnel to be demarcated from an acute STEMI diagnosis. 53 The COVID-19 screening at the emergency room must be implemented effectively and efficiently, and this can be achieved through good cooperation between staffs in interdepartmental level.

Other important criteria used as measures of successful performance in handling STEMI cases are the achievement of final TIMI 3 flow after primary PCI and the number of reported mortality cases. Inconsistent results among included studies with respect to the above two parameters were found in our analysis. The reason is that the final TIMI 3 flow rate after primary PCI and mortality rates were differ significantly in early COVID-19 outbreak, but not in the late pandemic period. It appears to suggest that the majority of studies included in the early pandemic subgroup were studies conducted at the pandemic focal point, namely United Kingdom 13 and Italy. 23, 34, 38 In addition, the majority of recorded studies presented in the late pandemic period conducted in countries of which the national or regional STEMI network has already been well developed. 54 Worse clinical outcome found in the early pandemic era, exhibit an unpreparedness and delay in times of system that influence performance of STEMI care. And yet, on the other hand, the performance of STEMI care during the pandemic period has gradually improved, which is indicated by no statistically significant difference between the two periods in the late pandemic subgroup analysis.

Admittedly, this study is also subject to several limitations. Firstly, the majority of studies did not include articles that took 

This meta-analysis shows that there has been a decline in the performance of STEMI systems of care and a deterioration of clinical outcomes in STEMI patients during the COVID-19 pandemic, particularly in the early pandemic period. The yield trend in the late pandemic era shows superior results and is expected to continue becoming better from now onwards.

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. 

COVID-19 Situation Reports

Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China

Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic

The obstacle course of reperfusion for STsegment-elevation myocardial infarction in the COVID-19 pandemic

Covid-19 and cardiovascular disease

Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era

Effect of the COVID-19 pandemic on ST-segment-elevation myocardial infarction presentations and in-hospital outcomes

Preferred reporting Items for systematic reviews and meta-analyses: the PRISMA statement

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

Director-General's Opening Remarks at the Media Briefing on COVID-19 -11

Impact of COVID-19 pandemic on patients with ST-segment elevation myocardial infarction: insights from a British cardiac center

The impact of COVID-19 pandemic on the presentation and hospital management of STEMI patients in a tertiary care center in Saudi arabia

Impact of the COVID-19 pandemic on door-toballoon time for primary percutaneous coronary intervention -results from the Singapore western STEMI network

Effect of the COVID-19 pandemic on access to primary percutaneous coronary intervention for ST-segment elevation myocardial infarction

Impact of COVID-19-related public containment measures on the ST elevation myocardial infarction epidemic in Belgium: a nationwide, serial, cross-sectional study

Delays in ST-elevation myocardial infarction care during the COVID-19 lockdown: an observational study. CJC Open

STEMI and COVID-19 pandemic in Saudi arabia

Impact of COVID-19 pandemic on mechanical reperfusion for patients with STEMI

Performance of primary angioplasty for STEMI during the COVID-19 outbreak

COVID-19 impact on ST-elevation myocardial infarction incidence rate in a north-eastern Italian STEMI network: a U-shaped curve phenomenon

ST-Segment-Elevation myocardial infarction during COVID-19 pandemic: insights from a regional public service healthcare hub

The impact of lockdown enforcement during the SARSCoV-2 pandemic on the timing of presentation and early outcomes of patients with ST-elevation myocardial infarction

Impact of the COVID-19 pandemic on percutaneous coronary intervention in england: insights from the British cardiovascular intervention society PCI database cohort

Impact of the shift to a fibrinolysis-first strategy on care and outcomes of patients with ST-segment-elevation myocardial infarction during the COVID-19 pandemic-The experience from the largest cardiovascular-specific centre in China

The impact of a dedicated coronavirus disease 2019 primary angioplasty protocol on time components related to ST-segment elevation myocardial infarction management in a 24/7 primary percutaneous coronary intervention-capable hospital

Impact of COVID-19 outbreak on regional STEMI care in Germany

Impact of public health emergency response to COVID-19 on management and outcome for STEMI patients in beijing-A singlecenter historic control study

Effect of Covid-19 pandemic process on STEMI patients timeline

Impact of the 2019 novel coronavirus disease pandemic on the performance of a cardiovascular department in a nonepidemic center in beijing

Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry study

Who has seen patients with STsegment-elevation myocardial infarction? First results from Italian real-world coronavirus disease 2019

Early observations during the COVID-19 pandemic in cardiac catheterization procedures for ST-elevation myocardial infarction across ontario

Changes in characteristics and management among patients with ST-elevation myocardial infarction due to COVID-19 infection

Effect of the COVID-19 pandemic on treatment delays in patients with ST-segment elevation myocardial infarction

Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction

Impact of SARS-CoV-2 pandemic on ST-elevation myocardial infarction admissions and outcomes in a Portuguese primary percutaneous coronary intervention center: preliminary Data

The impact of the COVID-19 pandemic on acute coronary syndrome admissions to a tertiary care hospital in Portugal

Impact of the COVID-19 outbreak on hospitalizations and outcomes in patients with acute myocardial infarction in a Japanese Single Center

Six-month outcomes for COVID-19 negative patients with acute myocardial infarction before versus during the COVID-19 pandemic

Initial single center ST-segment elevation myocardial infarction experience in New York before and during the COVID-19 pandemic. Cardiovasc Revascularization Med

Percutaneous coronary intervention for STelevation myocardial infarction before and during COVID in New York

Treatment delays and in-hospital outcomes in acute myocardial infarction during the COVID-19 pandemic: a nationwide study

Acute ST-elevation myocardial infarction before and during the COVID-19 pandemic: what is the clinically significant difference? Cureus

Implications of COVID-19 on time-sensitive STEMI care: a report from a North American epicenter. Cardiovasc Revascularization Med

Admission of patients with STEMI since the outbreak of the COVID-19 pandemic: a survey by the European Society of Cardiology

Collateral damage of COVID-19 pandemic: delayed medical care

Late STEMI and NSTEMI patients' emergency calling in COVID-19 outbreak

How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital

Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials

Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management

A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction

None.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ihj.2021.06.009.

WK helped in the conception and design of the study, as well as performed the statistical analysis. WK, APS, MAR, and DRG were actively involved in literature search, study selection, data extraction, extensive review, and writing the manuscript. All authors read and approved the final version submitted for publication.

None declared.